2015

Wobus, M., Bornhauser, M., Jacobi, A., Krater, M., Otto, O., Ortlepp, C., Guck, J., Ehninger, G., Thiede, C. & Oelschlagel, U. (2015) Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia. Oncotarget, 6, 38804-38815.

Wenge, D.V., Felipe-Fumero, E., Angenendt, L., Schliemann, C., Schmidt, E., Schmidt, L.H., Thiede, C., Ehninger, G., Berdel, W.E., Arteaga, M.F. & Mikesch, J.H. (2015) MN1-Fli1 oncofusion transforms murine hematopoietic progenitor cells into acute megakaryoblastic leukemia cells. Oncogenesis, 4, e179.

Thol, F., Scherr, M., Kirchner, A., Shahswar, R., Battmer, K., Kade, S., Chaturvedi, A., Koenecke, C., Stadler, M., Platzbecker, U., Thiede, C., Schroeder, T., Kobbe, G., Bug, G., Ottmann, O., Hofmann, W.K., Kroger, N., Fiedler, W., Schlenk, R., Dohner, K., Dohner, H., Krauter, J., Eder, M., Ganser, A. & Heuser, M. (2015) Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia. Haematologica, 100, e122-124.

Teipel, R., Schetelig, J., Kramer, M., Schmidt, H., Schmidt, A.H., Thiede, C., Oelschlagel, U., Kroschinsky, F., Bornhauser, M., Ehninger, G. & Holig, K. (2015) Prediction of hematopoietic stem cell yield after mobilization with granulocyte-colony-stimulating factor in healthy unrelated donors. Transfusion, 55, 2855-2863.

Schetelig, J., Schaich, M., Schafer-Eckart, K., Hanel, M., Aulitzky, W.E., Einsele, H., Schmitz, N., Rosler, W., Stelljes, M., Baldus, C.D., Ho, A.D., Neubauer, A., Serve, H., Mayer, J., Berdel, W.E., Mohr, B., Oelschlagel, U., Parmentier, S., Rollig, C., Kramer, M., Platzbecker, U., Illmer, T., Thiede, C., Bornhauser, M. & Ehninger (2015) Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial. Leukemia, 29, 1060-1068.

Sauer, T., Arteaga, M.F., Isken, F., Rohde, C., Hebestreit, K., Mikesch, J.H., Stelljes, M., Cui, C., Zhou, F., Gollner, S., Baumer, N., Kohler, G., Krug, U., Thiede, C., Ehninger, G., Edemir, B., Schlenke, P., Berdel, W.E., Dugas, M. & Muller-Tidow, C. (2015) MYST2 acetyltransferase expression and Histone H4 Lysine acetylation are suppressed in AML. Exp Hematol, 43, 794-802 e794.

Rollig, C., Serve, H., Huttmann, A., Noppeney, R., Muller-Tidow, C., Krug, U., Baldus, C.D., Brandts, C.H., Kunzmann, V., Einsele, H., Kramer, A., Schafer-Eckart, K., Neubauer, A., Burchert, A., Giagounidis, A., Krause, S.W., Mackensen, A., Aulitzky, W., Herbst, R., Hanel, M., Kiani, A., Frickhofen, N., Kullmer, J., Kaiser, U., Link, H., Geer, T., Reichle, A., Junghanss, C., Repp, R., Heits, F., Durk, H., Hase, J., Klut, I.M., Illmer, T., Bornhauser, M., Schaich, M., Parmentier, S., Gorner, M., Thiede, C., von Bonin, M., Schetelig, J., Kramer, M., Berdel, W.E. & Ehninger, G. (2015) Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol, 16, 1691-1699.

Rollig, C., Schafer-Eckardt, K., Hanel, M., Kramer, M., Schaich, M., Thiede, C., Oelschlagel, U., Mohr, B., Wagner, T., Einsele, H., Krause, S.W., Bodenstein, H., Martin, S., Stuhlmann, R., Ho, A.D., Bornhauser, M., Ehninger, G., Schuler, U. & Platzbecker, U. (2015) Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia. Results from the SAL-AIDA2000 trial. Ann Hematol, 94, 557-563.

Rollig, C., Bornhauser, M., Kramer, M., Thiede, C., Ho, A.D., Kramer, A., Schafer-Eckart, K., Wandt, H., Hanel, M., Einsele, H., Aulitzky, W.E., Schmitz, N., Berdel, W.E., Stelljes, M., Muller-Tidow, C., Krug, U., Platzbecker, U., Wermke, M., Baldus, C.D., Krause, S.W., Stolzel, F., von Bonin, M., Schaich, M., Serve, H., Schetelig, J. & Ehninger, G. (2015) Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial. J Clin Oncol, 33, 403-410.

Oelschlaegel, U., Westers, T.M., Mohr, B., Kramer, M., Parmentier, S., Sockel, K., Thiede, C., Bornhauser, M., Ehninger, G., van de Loosdrecht, A.A. & Platzbecker, U. (2015) Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring. Haematologica, 100, e93-96.

Heuser, M., Meggendorfer, M., Cruz, M.M., Fabisch, J., Klesse, S., Kohler, L., Gohring, G., Ganster, C., Shirneshan, K., Gutermuth, A., Cerny-Reiterer, S., Kronke, J., Panagiota, V., Haferlach, C., Koenecke, C., Platzbecker, U., Thiede, C., Schroeder, T., Kobbe, G., Ehrlich, S., Stamer, K., Dohner, K., Valent, P., Schlegelberger, B., Kroeger, N., Ganser, A., Haase, D., Haferlach, T. & Thol, F. (2015) Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q. Leukemia, 29, 1942-1945.